2Dovern GV.Antimicrobial use and the emergence of antimicrobial resistance with streptococcus pneumoniae in the United States[J].Clin Infect Dis,2001,33(suppl 3):S187-192.
3Dolhoff A,Petersen U,Endermann R.In vitro activity of BAY 12-8039,a new 8-methoxyquinolo[J].Chemotherapy,1996,42:410-425.
4Andrews JM,Honeybourne D,Jevons G,et al.Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre optic bronchoscopy[J].J Antimicrob Chemother,1997,40:573-577.
5Soman A,Honeybourne D,Andrews J,et al.Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy[J].J Antimicrob Chemother,1999,44:835-838.
6Niederman MS,Mandell LA,Anzueto A,et al.Guidelines for the Management of Adults with Commnuity-acquired Pneumonia.Diagnosis,assessment of severity,antimicrobial therapy and prevention[J].Am J Respir Crit Care Med,2001,163:1730-1754.
8Lim WS,Macfarlane JT,Boswell TC,et al.Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital:implications for management guidelines[J].Thorax,2001,56:296-301.
9Dudas V,Hopefl A,Jacobs R,et al.Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia:a survey of non teaching US community hospitals[J].Ann Pharmacother,2000,34:446-452.
10Fine MJ,Auble TE,Yealy DM,et al.A prediction rule to identify low risk patients with community acquired pneumonia[J].N Engl J Med,1997,336:243-250.
